Omeros (OMER) – Major News
-
Omeros (OMER) Misses Q3 EPS by 21c
-
Omeros (OMER) says narsoplimab did not achieve statistically significant improvement over placebo in Phase 3 trial
-
Omeros (OMER) Misses Q2 EPS by 13c
-
Omeros (OMER) Misses Q1 EPS by 4c
-
Omeros (OMER) Misses Q4 EPS by 40c
-
Omeros (OMER) Tops Q3 EPS by 16c
-
Omeros (OMER) Tops Q2 EPS by 11c
-
Omeros (OMER) Reports In-Line Q1 EPS, Revenues Beat
-
Omeros (OMER) Tops Q4 EPS by 4c
-
Omeros (OMER) Tops Q3 EPS by 27c, Revenues Beat
-
Omeros (OMER) Misses Q1 EPS by 19c, Revenues Miss
-
Omeros (OMER) Misses Q4 EPS by 8c, Revenues Beat
-
Omeros (OMER) Tops Q3 EPS by 8c, Revenues Beat
-
Omeros (OMER) Tops Q2 EPS by 17c, Revenues Beat
-
Omeros (OMER) Tops Q4 EPS by 19c, Revenues Beat
-
Omeros (OMER) Reports Additional Data for OMS721 in IgA Nephropathy
-
Omeros (OMER) Misses Q2 EPS by 1c
-
Omeros (OMER) Misses Q1 EPS by 19c
-
Omeros (OMER) Misses Q4 Loss Per Share of 34c
-
Omeros (OMER) Tops Q3 EPS by 17c
-
Omeros (OMER) Tops Q2 EPS by 5c, Beats on Revenues
-
Omeros (OMER) Tops Q1 EPS by 1c
-
Omeros (OMER) Tops Q4 EPS by 11c
-
Omeros (OMER) Tops Q3 EPS by 6c
-
Omeros (OMER) Tops Q2 EPS by 18c
-
Omeros (OMER) Misses Q1 EPS by 11c
-
Omeros (OMER) Tops Q4 Loss Per Share of 52c
-
Omeros (OMER) Tops Q3 EPS by 1c
-
Omeros (OMER) Announces Additional Positive OMS721 Phase 2 Data
-
Omeros (OMER) Tops Q2 EPS by 12c
-
Omeros (OMER) Tops Q1 EPS by 12c
-
Omeros (OMER) Tops Q4 EPS by 1c
-
Omeros (OMER) Tops Q1 EPS by 5c
-
Omeros Corp. (OMER) Suspends Huntington's Trial of OMS824
-
Omeros Corp. (OMER) Receives FDA Approval of Omidria
-
Omeros Corp. (OMER) Posts Q1 Loss of 54c/Share
-
Omeros Corp. (OMER) Posts Q4 Loss of 5c/Share
-
Omeros Corp. (OMER) Posts Q3 Loss of 46c/Share
-
Omeros Corp. (OMER) Misses Q2 EPS by 10c
-
Omeros Corp. (OMER) Reports In-Line Q1 EPS
-
Omeros (OMER) Said Symptoms Subscale of the KOOS for OMS103HP Did Not Reach Statistical Significance
-
Omeros Corp. (OMER) Misses Q3 EPS by 17c
-
Omeros Corp. (OMER) Misses Q1 EPS by 4c
-
Omeros Corp. (OMER) Posts Wider than Expected Q4 Loss of 46c/Share
-
Omeros Corp. (OMER) Tops Q3 EPS Views
-
Omeros Corporation (OMER) Posts Q2 EPS Loss of $0.24
-
Omeros Corporation (OMER) Posts Q1 loss of $0.30, Narrower than Views
-
Omeros Corp. (OMER) Tops Q4 Views
-
Omeros Corp (OMER) Posts Q3 Loss of $0.35, Narrower than Views
-
Omeros Corp. (OMER) Posts Mixed Q2 Results
Back to OMER Stock Lookup